1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
2
|
No authors listed. Esophageal cancer:
epidemiology, pathogenesis and prevention. Nat Clin Pract
Gastroenterol Hepatol. 5:517–526. 2008. View Article : Google Scholar
|
3
|
Mehlen P and Puisieux A: Metastasis: a
question of life or death. Nat Rev Cancer. 6:449–458. 2006.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Tian X, Liu Z, Niu B, et al:
E-cadherin/beta-catenin complex and the epithelial barrier. J
Biomed Biotechnol. 2011:5673052011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Hu Q, Guo C, Li Y, Aronow BJ and Zhang J:
LMO7 mediates cell-specific activation of the Rho-myocardin-related
transcription factor-serum response factor pathway and plays an
important role in breast cancer cell migration. Mol Cell Biol.
31:3223–3240. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Choi HN, Kim KR, Lee JH, et al: Serum
response factor enhances liver metastasis of colorectal carcinoma
via alteration of the E-cadherin/beta-catenin complex. Oncol Rep.
21:57–63. 2009.PubMed/NCBI
|
7
|
Farra R, Dapas B, Pozzato G, et al: Serum
response factor depletion affects the proliferation of the
hepatocellular carcinoma cells HepG2 and JHH6. Biochimie.
92:455–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kim KR, Bae JS, Choi HN, et al: The role
of serum response factor in hepatocellular carcinoma: an
association with matrix metalloproteinase. Oncol Rep. 26:1567–1572.
2011.PubMed/NCBI
|
9
|
Kim HJ, Kim KR, Park HS, et al: The
expression and role of serum response factor in papillary carcinoma
of the thyroid. Int J Oncol. 35:49–55. 2009.PubMed/NCBI
|
10
|
Kwon CY, Kim KR, Choi HN, et al: The role
of serum response factor in hepatocellular carcinoma: implications
for disease progression. Int J Oncol. 37:837–844. 2010.PubMed/NCBI
|
11
|
Park MY, Kim KR, Park HS, et al:
Expression of the serum response factor in hepatocellular
carcinoma: implications for epithelial-mesenchymal transition. Int
J Oncol. 31:1309–1315. 2007.PubMed/NCBI
|
12
|
Zhe X, Yang Y and Schuger L: Imbalanced
plasminogen system in lymphangioleiomyomatosis: potential role of
serum response factor. Am J Respir Cell Mol Biol. 32:28–34. 2005.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Rimerman RA, Gellert-Randleman A and Diehl
JA: Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and
cellular transformation. J Biol Chem. 275:14736–14742. 2000.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Shtutman M, Zhurinsky J, Simcha I, et al:
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.
Proc Natl Acad Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
|
15
|
Pradeep A, Sharma C, Sathyanarayana P, et
al: Gastrin-mediated activation of cyclin D1 transcription involves
beta-catenin and CREB pathways in gastric cancer cells. Oncogene.
23:3689–3699. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Song BJ, Park YJ, Kim HS, Kim CN and Chang
SH: Expression of beta-catenin and E-cadherin in early gastric
cancer: correlation with clinicopathologic parameters. Korean J
Gastroenterol. 43:82–89. 2004.(In Korean).
|
17
|
Jiang H, Xia J, Kang J, Ding Y and Wu W:
Short hairpin RNA targeting beta-catenin suppresses cell
proliferation and induces apoptosis in human gastric carcinoma
cells. Scand J Gastroenterol. 44:1452–1462. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Luo KJ, Hu Y, Wen J and Fu JH: CyclinD1,
p53, E-cadherin, and VEGF discordant expression in paired regional
metastatic lymph nodes of esophageal squamous cell carcinoma: a
tissue array analysis. J Surg Oncol. 104:236–243. 2011. View Article : Google Scholar : PubMed/NCBI
|